Tags

Type your tag names separated by a space and hit enter

Comparison of Epstein-Barr virus DNA level in plasma, peripheral blood cell and tumor tissue in nasopharyngeal carcinoma.
Anticancer Res. 2004 Nov-Dec; 24(6):4059-66.AR

Abstract

BACKGROUND

The plasma Epstein-Barr virus DNA (EBV-DNA) level has been found to be an indicator for staging and prognosis of nasopharyngeal carcinoma (NPC).

MATERIALS AND METHODS

The EBV-DNA level in plasma, peripheral blood cells (PBC) and neoplastic tissues was quantitatively analyzed and potential associations with clinical parameters of NPC were investigated.

RESULTS

The plasma EBV-DNA detecting rate and level in NPC (92%, 82,500 copies/ml) was significantly higher than that in NPC after treatment (19%, 0 copy/ml) and in controls (12%, 0 copy/ml) (p < 0.001); while there was no significance of the PBC EBV-DNA detecting rate and EBV-DNA load in NPC before (24%, 0 copy/actin) and after treatment (14%, 0 copy/actin), and in controls (16%, 0 copy/actin). The plasma EBV-DNA level was not correlated to the PBC EBV-DNA load in NPC before (p = 0.92) and after treatment (p = 0.267), and in controls (p = 0.735). The EBV-DNA level in NPC tumor (27.8 copies/actin) was significantly higher than that in nasopharyngitis and was positively correlated to the ratio of EBER1-positive cells on the NPC section (p = 0.001). The plasma EBV-DNA level was significantly increased in TNM stages I, II, III and IV NPC, whereas there was no significant difference of PBC EBV-DNA load in different stage NPC.

CONCLUSION

Our results indicate that plasma EBV-DNA is a more sensitive and reliable biomarker than PBC EBV-DNA for diagnosis, staging and therapeutic effect evaluation at a molecular level in NPC clinical practice. Plasma EBV-DNA may derive from the cancer cells and PBC EBV-DNA from circulating mononuclear cells in NPC patients.

Authors+Show Affiliations

Department of Pathology, Sun Yat-sen University, Guangzhou, P R China. jyshao@gzsums.edu.cnNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15736452

Citation

Shao, Jian-Yong, et al. "Comparison of Epstein-Barr Virus DNA Level in Plasma, Peripheral Blood Cell and Tumor Tissue in Nasopharyngeal Carcinoma." Anticancer Research, vol. 24, no. 6, 2004, pp. 4059-66.
Shao JY, Zhang Y, Li YH, et al. Comparison of Epstein-Barr virus DNA level in plasma, peripheral blood cell and tumor tissue in nasopharyngeal carcinoma. Anticancer Res. 2004;24(6):4059-66.
Shao, J. Y., Zhang, Y., Li, Y. H., Gao, H. Y., Feng, H. X., Wu, Q. L., Cui, N. J., Cheng, G., Hu, B., Hu, L. F., Ernberg, I., & Zeng, Y. X. (2004). Comparison of Epstein-Barr virus DNA level in plasma, peripheral blood cell and tumor tissue in nasopharyngeal carcinoma. Anticancer Research, 24(6), 4059-66.
Shao JY, et al. Comparison of Epstein-Barr Virus DNA Level in Plasma, Peripheral Blood Cell and Tumor Tissue in Nasopharyngeal Carcinoma. Anticancer Res. 2004 Nov-Dec;24(6):4059-66. PubMed PMID: 15736452.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparison of Epstein-Barr virus DNA level in plasma, peripheral blood cell and tumor tissue in nasopharyngeal carcinoma. AU - Shao,Jian-Yong, AU - Zhang,Yu, AU - Li,Yu-Hong, AU - Gao,Hong-Yi, AU - Feng,Hui-Xia, AU - Wu,Qiu-Liang, AU - Cui,Nian-Ji, AU - Cheng,Gang, AU - Hu,Bin, AU - Hu,Li-Fu, AU - Ernberg,Ingemar, AU - Zeng,Yi-Xin, PY - 2005/3/2/pubmed PY - 2005/3/23/medline PY - 2005/3/2/entrez SP - 4059 EP - 66 JF - Anticancer research JO - Anticancer Res VL - 24 IS - 6 N2 - BACKGROUND: The plasma Epstein-Barr virus DNA (EBV-DNA) level has been found to be an indicator for staging and prognosis of nasopharyngeal carcinoma (NPC). MATERIALS AND METHODS: The EBV-DNA level in plasma, peripheral blood cells (PBC) and neoplastic tissues was quantitatively analyzed and potential associations with clinical parameters of NPC were investigated. RESULTS: The plasma EBV-DNA detecting rate and level in NPC (92%, 82,500 copies/ml) was significantly higher than that in NPC after treatment (19%, 0 copy/ml) and in controls (12%, 0 copy/ml) (p < 0.001); while there was no significance of the PBC EBV-DNA detecting rate and EBV-DNA load in NPC before (24%, 0 copy/actin) and after treatment (14%, 0 copy/actin), and in controls (16%, 0 copy/actin). The plasma EBV-DNA level was not correlated to the PBC EBV-DNA load in NPC before (p = 0.92) and after treatment (p = 0.267), and in controls (p = 0.735). The EBV-DNA level in NPC tumor (27.8 copies/actin) was significantly higher than that in nasopharyngitis and was positively correlated to the ratio of EBER1-positive cells on the NPC section (p = 0.001). The plasma EBV-DNA level was significantly increased in TNM stages I, II, III and IV NPC, whereas there was no significant difference of PBC EBV-DNA load in different stage NPC. CONCLUSION: Our results indicate that plasma EBV-DNA is a more sensitive and reliable biomarker than PBC EBV-DNA for diagnosis, staging and therapeutic effect evaluation at a molecular level in NPC clinical practice. Plasma EBV-DNA may derive from the cancer cells and PBC EBV-DNA from circulating mononuclear cells in NPC patients. SN - 0250-7005 UR - https://www.unboundmedicine.com/medline/citation/15736452/Comparison_of_Epstein_Barr_virus_DNA_level_in_plasma_peripheral_blood_cell_and_tumor_tissue_in_nasopharyngeal_carcinoma_ L2 - http://ar.iiarjournals.org/cgi/pmidlookup?view=long&amp;pmid=15736452 DB - PRIME DP - Unbound Medicine ER -